Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alebund Pharmaceuticals (Hong Kong) Ltd.
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Apr 12, 2023
Deals
April 12 Quick Takes: Function Oncology launches with $28M
Plus: Biogen exercises option for Denali β-amyloid program and updates from ImmuneBridge, Nature, Aspect-Novo and more
BioCentury | Oct 19, 2021
Product Development
Assessing Biogen’s ALS miss, plus Califf on deck
Can Biogen push another neurodegeneration therapy across the goal line at FDA?
BioCentury | Oct 12, 2021
Emerging Company Profile
LAV’s Xia parlays gap in kidney therapies into China start-up
With $150M in funding, Alebund is building a pipeline of homegrown and in-licensed assets with a focus on renal disease
BioCentury | May 11, 2021
Finance
May 10 Quick Takes: Novavax sinks on vaccine submission delay; plus Alebund, Gennao, Therini, Singular Genomics and more
After closing down $15.50 (9%) to $160.50 Monday, Novavax Inc. (NASDAQ:NVAX) shed an additional 11% in after-hours trading following its announcement that the company will file for emergency
Items per page:
1 - 5 of 5